WallStreetZenWallStreetZen

NASDAQ: CBIO
Crescent Biopharma Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for CBIO

Based on 5 analysts offering 12 month price targets for Crescent Biopharma Inc

Min Forecast
$22.00+76.14%
Avg Forecast
$25.60+104.96%
Max Forecast
$28.00+124.18%

Should I buy or sell CBIO stock?

Based on 5 analysts offering ratings for Crescent Biopharma Inc.

Strong Buy
Strong Buy
2 analysts 40%
Buy
3 analysts 60%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although CBIO's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates CBIO as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their CBIO stock forecasts and price targets.

CBIO stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-08-27
lockedlocked$00.00+00.00%2025-08-25
lockedlocked$00.00+00.00%2025-07-14
lockedlocked$00.00+00.00%2025-06-25
lockedlocked$00.00+00.00%2025-06-18

1 of 1

Forecast return on equity

Is CBIO forecast to generate an efficient return?

Company
-49.78%
Industry
130.75%
Market
-52.16%
CBIO's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is CBIO forecast to generate an efficient return on assets?

Company
-44.03%
Industry
47.72%
CBIO is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

CBIO earnings per share forecast

What is CBIO's earnings per share in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
-$7.86
Avg 2 year Forecast
-$4.17
Avg 3 year Forecast
-$3.58

CBIO revenue forecast

What is CBIO's revenue in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
$22.5M
Avg 2 year Forecast
$30.0M
Avg 3 year Forecast
$30.0M

CBIO vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CBIO$12.49$25.60+104.96%Strong Buy
IVVD$1.43$3.67+156.43%Strong Buy
TVGN$0.87$10.00+1,054.73%Strong Buy
ENTA$8.28$23.00+177.78%Strong Buy
KYTX$3.92$11.67+197.63%Strong Buy
View Top Biotech Stocks

Crescent Biopharma Stock Forecast FAQ

Is Crescent Biopharma Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 5 Wall Street analysts covering (NASDAQ: CBIO) stock is to Strong Buy CBIO stock.

Out of 5 analysts, 2 (40%) are recommending CBIO as a Strong Buy, 3 (60%) are recommending CBIO as a Buy, 0 (0%) are recommending CBIO as a Hold, 0 (0%) are recommending CBIO as a Sell, and 0 (0%) are recommending CBIO as a Strong Sell.

If you're new to stock investing, here's how to buy Crescent Biopharma stock.

What is CBIO's earnings growth forecast for 2025-2027?

(NASDAQ: CBIO) Crescent Biopharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.16%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.29%.

Crescent Biopharma's earnings in 2025 is -$41,180,821.On average, 4 Wall Street analysts forecast CBIO's earnings for 2025 to be -$109,126,075, with the lowest CBIO earnings forecast at -$145,455,124, and the highest CBIO earnings forecast at -$83,355,372. On average, 4 Wall Street analysts forecast CBIO's earnings for 2026 to be -$57,966,715, with the lowest CBIO earnings forecast at -$76,270,165, and the highest CBIO earnings forecast at -$45,984,380.

In 2027, CBIO is forecast to generate -$49,735,372 in earnings, with the lowest earnings forecast at -$49,735,372 and the highest earnings forecast at -$49,735,372.

What is CBIO's revenue growth forecast for 2027-2029?

(NASDAQ: CBIO) Crescent Biopharma's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 86.2%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.83%.

Crescent Biopharma's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast CBIO's revenue for 2027 to be $312,582,645, with the lowest CBIO revenue forecast at $312,582,645, and the highest CBIO revenue forecast at $312,582,645. On average, 1 Wall Street analysts forecast CBIO's revenue for 2028 to be $416,776,860, with the lowest CBIO revenue forecast at $416,776,860, and the highest CBIO revenue forecast at $416,776,860.

In 2029, CBIO is forecast to generate $416,776,860 in revenue, with the lowest revenue forecast at $416,776,860 and the highest revenue forecast at $416,776,860.

What is CBIO's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: CBIO) forecast ROA is -44.03%, which is lower than the forecast US Biotechnology industry average of 47.72%.

What is CBIO's Price Target?

According to 5 Wall Street analysts that have issued a 1 year CBIO price target, the average CBIO price target is $25.60, with the highest CBIO stock price forecast at $28.00 and the lowest CBIO stock price forecast at $22.00.

On average, Wall Street analysts predict that Crescent Biopharma's share price could reach $25.60 by Aug 27, 2026. The average Crescent Biopharma stock price prediction forecasts a potential upside of 104.96% from the current CBIO share price of $12.49.

What is CBIO's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: CBIO) Crescent Biopharma's current Earnings Per Share (EPS) is -$34.93. On average, analysts forecast that CBIO's EPS will be -$7.86 for 2025, with the lowest EPS forecast at -$10.47, and the highest EPS forecast at -$6.00. On average, analysts forecast that CBIO's EPS will be -$4.17 for 2026, with the lowest EPS forecast at -$5.49, and the highest EPS forecast at -$3.31. In 2027, CBIO's EPS is forecast to hit -$3.58 (min: -$3.58, max: -$3.58).

What is CBIO's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: CBIO) forecast ROE is -49.78%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.